Fig. 1. MAHALO clinical trial flowchart.

Slides:

Advertisements

Similar presentations

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Advertisements

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.

Laser-Ranibizumab-Triamcinolone for DME Study DRCR.net Protocol I

The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.

NDA SE-011 Docetaxel FDA Review. FDA Review Team Biostatistics –Clara Chu, PhD. –Gang Chen, PhD. Biopharmaceutics –Safaa Ibrahim PhD –Atiq Rahman,

A Controlled Trial of Renal Denervation for Resistant Hypertension

1 Slides Shown at FDA Advisory Committee Eyetech Pharmaceuticals Pfizer, Inc. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting 27 August 2004.

STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

Sponsored by the National Eye Institute,

SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.

Thrice-Weekly Glatiramer Acetate for Relapsing Forms of Multiple Sclerosis: Findings from the GALA Study Fred D. Lublin, MD Saunders Family Professor of.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.

Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:

Secondary Analysis of Clinical Trials Data – A Biostatistician’s Experience Gui-shuang Ying, PhD Center for Preventive Ophthalmology and Biostatistics.

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial

Glecaprevir-Pibrentasvir in GT 1-6 with Renal Disease EXPEDITION-4

Lack of Evidence of a Clopidogrel – Statin Interaction in the CHARISMA Trial J Am Coll Cardiol 2007;50:291-5 Jacqueline Saw, MD*, Danielle Brennan, MS†,

Etravirine in Treatment Experienced DUET-2 (TMC125-C216)

Outer Retinal Tubulation as a Predictor of the Growth Rate of Geographic Atrophy in Age Related Macular Degeneration Amirhossein Hariri 1, Muneeswar G.

Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Etravirine in Treatment Experienced DUET-1 (TMC125-C206)

Valsartan in Acute Myocardial Infarction Trial Investigators

Thadhani et al. Am J Nephrol 2017;45:40-48 (DOI: / )

Dry AMD and GA: The Present and Future

Phase 2 Treatment Naïve Injection Drug Use

Geographic Atrophy in a Clinical Trial Environment

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Krop I et al. SABCS 2009;Abstract 5090.

Bergh J et al. SABCS 2009;Abstract 23.

Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease Torres et al. Am J.

Fig. 2. Mutational signature exposures in Taiwan HCCs and summary of AA signature mutations. Mutational signature exposures in Taiwan HCCs and summary.

Fig. 6. C3 deficiency resulted in partial sparing of neuron loss in hippocampal CA3 in 16-month-old APP/PS1 mice. C3 deficiency resulted in partial sparing.

Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment.

Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 5. Preliminary performance validation of the hydrogel in vivo in a rabbit model of scleral trauma. Preliminary performance validation of the hydrogel.

Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 4. MATE1 transcription in RCC.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Intervista a Filippo de Marinis

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

CoPrincipal Investigators

Fig. 7 Human study design for device testing.

Fig. 3. The effects of DCA on hemodynamic and functional end points and their association with genetic factors (variants of the SIRT3 and UCP2 genes) that.

Fig. 4. Analysis of T cell responses according to treatment and in peptide-treated C-peptide responders and nonresponders. Analysis of T cell responses.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Flow of Patients Through the Trial

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year.

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.

Phase 3 Treatment-Naïve and Treatment-Experienced

FIGURE 1. Flowchart of PnCRM7 clinical trial participants, primary efficacy cohort, and sub-populations used for efficacy analyses. Clinical trial participants.

A1C at baseline and each maintenance month by treatment in the GEMINI trial, including the modified intention-to-treat population. A1C at baseline and.

Translating Data From Trial to Practice

Presentation transcript:

Fig. 1. MAHALO clinical trial flowchart. MAHALO clinical trial flowchart. This was a phase 2, multicenter, randomized, controlled study that investigated the safety, tolerability, pharmacokinetics, and evidence of activity of lampalizumab in patients with geographic atrophy secondary to AMD. One hundred twenty-nine eligible patients were randomized 1:2:1:2 to sham monthly, 10-mg lampalizumab monthly, sham every other month, or 10-mg lampalizumab every other month. *One hundred twenty-three patients met the prespecified modified intention-to-treat (mITT) criteria for primary efficacy analysis. This population included all randomized patients who had one or more treatment injections and one or more post-baseline geographic atrophy measurements. Sham arms were pooled for analyses. Brian L. Yaspan et al., Sci Transl Med 2017;9:eaaf1443 Published by AAAS